Verona Pharma to Present at Two Upcoming Investor Conferences

LONDON, Oct. 31, 2017 -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today that Jan-Anders Karlsson, PhD, CEO of Verona Pharma, is scheduled to present at the following upcoming investor conferences:  

Event: Stifel 2017 Healthcare Conference
Date: November 14, 2017
Time: 11:00 AM EST
Location: New York, NY

Event: Jefferies 2017 London Healthcare Conference
Date: November 16, 2017
Time: 2:40 PM GMT
Location: London, UK

An updated version of the investor presentation will be available in the Investors section of the Verona website http://www.veronapharma.com/.

About Verona Pharma plc

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma’s product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has been observed to result in statistically significant improvements in lung function as compared to placebo, and has shown clinically meaningful and statistically significant improvements in lung function when administered in addition to frequently used short- and long-acting bronchodilators as compared to such bronchodilators administered as a single agent. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF), and potentially asthma. 

For further information, please contact: